{"entity":{"id":"nct02542293","kind":"trial","name":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)","aka":["NEPTUNE"],"tldr":"A phase 3 trial of Durvalumab, Tremelimumab, Carboplatin, Gemcitabine + cisplatin, Gemcitabine and Cisplatin in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","summary":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) is a phase 3 interventional study registered as NCT02542293 by AstraZeneca, with 953 participants enrolled, started 2015-11-03 and due to reach its primary completion in 2020-09-21. Interventions recorded: Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin and Pemetrexed + carboplatin. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02542293","url":"https://clinicaltrials.gov/study/NCT02542293"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["durvalumab","tremelimumab","carboplatin","gemcitabine-cisplatin","gemcitabine","cisplatin"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02542293","phase":"3","setting":"A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).","sponsor":"AstraZeneca","started":"2015-11-03","startedType":"actual","yearReported":2022,"enrolled":953,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set","primary":true,"unit":"months","arms":[{"name":"Global: Durvalumab + Tremelimumab","n":69,"value":11.7,"note":"95% CI 8.6 to 15.2; Figures from the ClinicalTrials.gov results section (first posted 2022-05-24), not from a publication"},{"name":"Global: SoC Chemotherapy","n":60,"value":9.1,"note":"95% CI 7.8 to 12.6"}],"hr":0.71,"ci":[0.485,1.045],"p":"0.0808","source":"https://clinicaltrials.gov/study/NCT02542293?tab=results"},{"endpoint":"OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set","primary":true,"unit":"months","arms":[{"name":"China: Durvalumab + Tremelimumab","n":26,"value":15,"note":"95% CI 10.5 to 27.4; Figures from the ClinicalTrials.gov results section (first posted 2022-05-24), not from a publication"},{"name":"China: SoC Chemotherapy","n":29,"value":11.7,"note":"95% CI 8.6 to 20.5"}],"hr":0.6,"ci":[0.322,1.109],"source":"https://clinicaltrials.gov/study/NCT02542293?tab=results"}]},"route":"/trials/nct02542293/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"gemcitabine-cisplatin","kind":"drug","name":"Gemcitabine + cisplatin","route":"/drugs/gemcitabine-cisplatin/"},{"id":"tremelimumab","kind":"drug","name":"Tremelimumab","route":"/drugs/tremelimumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"term":[{"id":"lung-failed-programmes","kind":"term","name":"Lung cancer: the failed and stopped programmes, and why","route":"/terms/lung-failed-programmes/"}],"trial":[{"id":"nct03164616","kind":"trial","name":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","route":"/trials/nct03164616/"}]}}